IceCure Medical Ltd. Announces $5.5 Million Private Placement and Warrant Amendments

IceCure Medical Ltd. has entered into a Securities Purchase Agreement for a private placement of pre-funded warrants and Series D and E warrants to purchase ordinary shares. The offering is expected to raise approximately $5.5 million. The company also amended existing warrants to reduce the exercise price to $3.00 per share, subject to shareholder approval. The proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners was engaged as the placement agent. The company has agreed to file a resale registration statement for the offered shares. Additionally, IceCure announced significant growth in its U.S. commercial install base for breast cancer cryoablation following FDA clearance.